Salvatore Siena
#117,355
Most Influential Person Now
Researcher ORCID: 0000-0002-2681-2846
Salvatore Siena's AcademicInfluence.com Rankings
Salvatore Sienacomputer-science Degrees
Computer Science
#4623
World Rank
#4876
Historical Rank
Machine Learning
#965
World Rank
#979
Historical Rank
Artificial Intelligence
#1185
World Rank
#1206
Historical Rank
Database
#1830
World Rank
#1919
Historical Rank
Download Badge
Computer Science
Salvatore Siena's Degrees
- Masters Computer Engineering University of Milan
- Bachelors Information Technology University of Florence
Similar Degrees You Can Earn
Why Is Salvatore Siena Influential?
(Suggest an Edit or Addition)Salvatore Siena's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (2004) (3841)
- Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. (2008) (2486)
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (2113)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) (1968)
- Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013) (1947)
- Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. (2007) (1867)
- Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. (2010) (1675)
- Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. (2008) (1616)
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer (2012) (1611)
- Integrating liquid biopsies into the management of cancer (2017) (1235)
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014) (1090)
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. (2005) (968)
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (2015) (823)
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011) (794)
- PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. (2009) (764)
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010) (714)
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. (2019) (711)
- Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. (2010) (665)
- GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION (1989) (651)
- Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. (2007) (645)
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) (639)
- A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. (2003) (570)
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). (2017) (561)
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. (2013) (560)
- Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. (1991) (558)
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer (2009) (543)
- Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. (1989) (520)
- High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. (1997) (504)
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. (2012) (491)
- Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. (2002) (482)
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth (2017) (397)
- Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. (2014) (394)
- NTRK gene fusions as novel targets of cancer therapy across multiple tumour types (2016) (391)
- The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer (2015) (381)
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. (2018) (368)
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. (2014) (363)
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. (2016) (319)
- Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. (2007) (318)
- Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. (2000) (311)
- HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. (2005) (292)
- Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). (2007) (287)
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. (2015) (281)
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer (2009) (275)
- Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. (2007) (274)
- Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study (2012) (274)
- Early‐onset colorectal cancer in young individuals (2018) (267)
- Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. (2005) (260)
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015) (243)
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (2019) (241)
- Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. (1995) (240)
- First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. (2012) (233)
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer (2014) (232)
- Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. (2008) (230)
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets (2015) (230)
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer (2013) (229)
- Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. (2012) (221)
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. (2015) (218)
- Adaptive mutability of colorectal cancers in response to targeted therapies (2019) (211)
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study (2015) (199)
- Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. (1997) (195)
- Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. (1990) (190)
- Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autransplantation. (1989) (184)
- Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (2008) (171)
- KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy (2013) (168)
- An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. (2008) (163)
- Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies (2017) (159)
- Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer (2017) (156)
- Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer (2016) (149)
- Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer (2018) (147)
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. (2020) (145)
- Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib (2009) (145)
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) (2009) (140)
- Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy (2009) (139)
- BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. (2015) (139)
- Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. (1992) (137)
- H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). (2001) (135)
- Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. (2008) (134)
- Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo‐radiotherapy? (1989) (128)
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer (2015) (127)
- Allogeneic blood stem cell transplantation after a reduced‐intensity, preparative regimen (2002) (126)
- The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition (2014) (120)
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. (2021) (118)
- Acquired resistance to EGFR‐targeted therapies in colorectal cancer (2014) (118)
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study) (2016) (116)
- Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. (1997) (114)
- Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer (2009) (111)
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. (2014) (109)
- Targeted therapies: how personal should we go? (2012) (108)
- Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. (2018) (104)
- Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. (2009) (104)
- A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. (2003) (104)
- Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. (2008) (102)
- Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. (2015) (98)
- Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer (2013) (97)
- Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. (1999) (96)
- Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (2015) (96)
- Malignant peritoneal mesothelioma: a multicenter study on 81 cases. (2010) (96)
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study (2009) (96)
- Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis (2017) (93)
- Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. (2004) (91)
- Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. (2006) (90)
- 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial (2009) (89)
- Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab (2007) (88)
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. (2016) (86)
- Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow. (1985) (82)
- Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer (2013) (82)
- Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer (2018) (80)
- Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. (1991) (79)
- High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. (1994) (79)
- Exploring the links between cancer and placenta development (2018) (78)
- Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. (1990) (78)
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer (2019) (77)
- Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. (1991) (76)
- Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. (2012) (76)
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial (2018) (74)
- Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. (2013) (73)
- Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. (1991) (71)
- High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update. (1993) (71)
- Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. (1998) (71)
- Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. (1994) (70)
- HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. (2019) (70)
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial (2020) (68)
- Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). (2014) (68)
- Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer (2015) (67)
- Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. (2015) (66)
- Precision oncology in metastatic colorectal cancer — from biology to medicine (2021) (66)
- Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. (1990) (66)
- Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). (2013) (66)
- The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer (2017) (63)
- Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer (2017) (62)
- Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (2015) (60)
- A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin (2019) (60)
- Survival of adults treated for medulloblastoma using paediatric protocols. (2005) (58)
- Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. (2019) (57)
- Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999 (2003) (56)
- T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. (2012) (56)
- Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow. (1992) (56)
- Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). (2002) (55)
- Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. (2001) (54)
- Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) (2016) (53)
- Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. (1992) (52)
- Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. (1993) (52)
- Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates. (1988) (52)
- Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation (2005) (51)
- Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. (2016) (50)
- A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. (2008) (49)
- Alka-372-001: First-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations. (2015) (48)
- Reduced incidence of infusion‐related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication (2010) (48)
- EGFR FISH in colorectal cancer: what is the current reality? (2008) (47)
- Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). (2013) (46)
- Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers (2017) (46)
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. (2019) (45)
- Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study (2011) (45)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. (2012) (44)
- A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. (2019) (44)
- High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. (2006) (43)
- Flow cytometry to estimate circulating hematopoietic progenitors for autologous transplantation: comparative analysis of different CD34 monoclonal antibodies. (1991) (43)
- Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. (1989) (43)
- The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer. (2020) (43)
- Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts. (1994) (43)
- A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors (2018) (42)
- No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. (2011) (42)
- Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. (1993) (42)
- Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series (2008) (42)
- Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer (2017) (42)
- The best manuscript: Open-label phase 3 trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[含 解説者コメント] (2007) (42)
- Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. (2020) (41)
- Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer (2018) (41)
- Regorafenib in metastatic colorectal cancer (2014) (41)
- Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. (2006) (40)
- Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. (2014) (40)
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer (2021) (40)
- First-line single-agent cetuximab in patients with advanced colorectal cancer. (2008) (40)
- Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (2012) (40)
- OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) (2018) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. (2014) (39)
- A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. (2019) (39)
- Effect of Primary Tumor Location on Second‐ or Later‐line Treatment Outcomes in Patients With RAS Wild‐type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies (2018) (39)
- Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas† (2016) (39)
- Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. (1996) (38)
- A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (2020) (38)
- Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. (2021) (38)
- Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. (1995) (37)
- Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer (2019) (37)
- MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. (2006) (37)
- Treatment of metastatic neuroendocrine carcinomas based on WHO classification. (2005) (37)
- Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer (2020) (36)
- Adenovirus vectors for gene transduction into mobilized blood CD34+ cells (1998) (36)
- Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. (1991) (36)
- B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells. (1989) (36)
- Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. (2019) (35)
- KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment (2011) (34)
- Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. (2016) (33)
- Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases (2013) (33)
- Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. (2010) (33)
- Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. (2013) (33)
- Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). (2011) (32)
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial (2022) (32)
- Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (2010) (32)
- Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. (2012) (31)
- Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. (2010) (31)
- Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients (2015) (31)
- Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) (2016) (31)
- Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m2) cyclophosphamide cancer therapy. (1993) (30)
- 7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy (2007) (30)
- Ex vivo expansion of hematopoietic cells and their clinical use. (1998) (30)
- The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer (2021) (29)
- Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. (2021) (29)
- Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. (2014) (29)
- Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. (2005) (29)
- Transfusion of platelet concentrates cryopreserved with ThromboSol plus low‐dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study (2000) (29)
- Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients (2013) (28)
- Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data (2008) (28)
- Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. (1996) (28)
- Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. (2014) (28)
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial (2022) (27)
- Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation. (1988) (27)
- Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC). (2012) (27)
- Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. (2016) (27)
- Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials (2018) (27)
- Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor (2017) (27)
- Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials (2017) (27)
- Long-term hematopoietic culture-initiating cells are more abundant in mobilized peripheral blood grafts than in bone marrow but have a more limited ex vivo expansion potential. (1996) (26)
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors (2022) (26)
- Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case (2018) (26)
- LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen (2021) (26)
- Liquid biopsy for rectal cancer: A systematic review. (2019) (26)
- Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression (2021) (25)
- Entrectinib for the treatment of metastatic NSCLC: safety and efficacy (2020) (25)
- Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases (2020) (25)
- An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer (2013) (25)
- Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC) (2011) (25)
- HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. (2016) (25)
- Ex vivo generation and expansion of anti‐tumor cytotoxic T‐cell lines derived from patients or their HLA‐identical sibling (2004) (25)
- Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ (2021) (24)
- Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies (2016) (24)
- Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. (2016) (24)
- Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. (2017) (24)
- Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers (2021) (24)
- Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin. (1987) (24)
- Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. (2015) (24)
- Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis. (2020) (23)
- An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. (2009) (23)
- CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions (2020) (23)
- Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression (2019) (23)
- High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib (2019) (23)
- GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. (2007) (23)
- Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells (1991) (23)
- A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. (2017) (23)
- Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results (2016) (23)
- Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2012) (22)
- Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. (2016) (22)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). (2021) (22)
- LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion (2022) (22)
- Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. (2020) (21)
- BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer (2020) (21)
- Strategies to tackle RAS-mutated metastatic colorectal cancer (2021) (21)
- New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. (1999) (21)
- Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients (2019) (21)
- Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells. (1988) (21)
- The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review (2020) (21)
- Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer (2017) (20)
- Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer (2013) (20)
- Estimation of peripheral blood CD34+ cells for autologous transplantation in cancer patients. (1993) (20)
- Radiomics predicts response of individual HER2‐amplified colorectal cancer liver metastases in patients treated with HER2‐targeted therapy (2020) (20)
- Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. (2003) (20)
- Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. (2015) (19)
- OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) (2017) (19)
- Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans. (1989) (19)
- Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. (2019) (19)
- Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy. (2003) (19)
- Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. (2013) (19)
- A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. (2019) (18)
- Cell-mediated immunity in children with chronic cholestasis. (1982) (18)
- Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study) (2008) (18)
- Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient. (2017) (18)
- Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies (2012) (17)
- The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. (2022) (17)
- Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial (2019) (17)
- Multiple serum inhibitors of lectin-induced lymphocyte proliferation in nephrotic syndrome. (1981) (17)
- Time course of regorafenib-associated adverse events in the phase III CORRECT study. (2013) (17)
- Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. (2020) (16)
- Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. (2018) (16)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. (2012) (16)
- 29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements (2015) (16)
- 7100 High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter Phase III Italian trial (2009) (16)
- Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial (2016) (15)
- GM-CSF-exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma. (1990) (15)
- Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials (2016) (15)
- Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study (2012) (15)
- Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient (2017) (15)
- KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. (2009) (15)
- The Effect of Anticonvulsant Drugs on Blood Levels of Methotrexate (2000) (15)
- Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation. (1990) (15)
- Liquid biopsies to monitor and direct cancer treatment in colorectal cancer (2022) (15)
- Rationale and clinical results of multi-target treatments in oncology. (2007) (15)
- Time course of regorafenib-associated adverse events in the phase III CORRECT study (2013) (14)
- Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience (2017) (14)
- Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies (2018) (14)
- Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. (2020) (14)
- Eucharistic problems for celiac patients. (1982) (14)
- Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients (2022) (14)
- Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). (2013) (13)
- O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001) (2020) (13)
- Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment (2021) (13)
- MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). (2021) (13)
- First-line single-agent cetuximab in patients with advanced colorectal cancer. (2006) (13)
- Transplantation of HLA-mismatched marrow depleted of T-cells by lectin agglutination and E-rosette depletion. (1985) (13)
- Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. (2013) (13)
- Iron supplementation and erythropoiesis‐stimulatory agents in the treatment of cancer anemia (2009) (13)
- The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. (2020) (13)
- Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label Sorafenib post-progression on the phase III decision trial (2015) (13)
- Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. (2022) (13)
- Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. (2019) (12)
- High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. (2015) (12)
- Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. (1990) (12)
- Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC). (2014) (12)
- D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer (2016) (12)
- Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). (2011) (12)
- Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. (2007) (12)
- Controversies in the management of brain metastases: the role of chemotherapy. (2001) (12)
- MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress. (2021) (12)
- SPECIFIC EX‐VIVO DEPLETION OF HUMAN BONE MARROW T LYMPHOCYTES BY AN ANTI‐PAN‐T CELL (CD5) RICINA‐CHAIN IMMUNOTOXIN (1987) (12)
- Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). (2012) (12)
- Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours (2021) (12)
- Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond (2021) (11)
- Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. (2018) (11)
- Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. (2019) (11)
- In vivo effects in mice of an anti-T cell immunotoxin. (1989) (11)
- Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
- Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). (2019) (11)
- Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. (2020) (11)
- TRKA expression and NTRK1 gene copy number across solid tumours (2018) (11)
- Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. (2013) (11)
- Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF. (1999) (11)
- Combined negative and positive selection of mobilized CD34+ blood cells (1996) (11)
- 547PIMPACT OF BASELINE AGE ON EFFICACY AND SAFETY OF FIRST-LINE PANITUMUMAB (PMAB) + FOLFOX4 VS FOLFOX4 TREATMENT. (2014) (10)
- Circulating hemopoietic progenitors mobilized by cancer chemotherapy and by rhGM-CSF in the treatment of high-grade non-Hodgkin's lymphoma. (1991) (10)
- Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study (2007) (10)
- Measurement of marrow repopulating potential of human hematopoietic progenitor and stem cells using a fetal sheep model. (1994) (10)
- Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s) (1993) (10)
- Mobilized peripheral blood CD34+ cells express more amphotropic retrovirus receptor than bone marrow CD34+ cells. (1998) (10)
- Receptors for peanut agglutinin on a high percentage of human cord-blood lymphocytes: phenotype characterization of peanut-positive cells. (1981) (10)
- Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. (2006) (10)
- Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial (2018) (10)
- Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA (2021) (10)
- Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC) (2010) (10)
- Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma (2008) (9)
- Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab) (2007) (9)
- Practical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients (1992) (9)
- Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. (2016) (9)
- Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials (2018) (9)
- Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (N (2012) (9)
- Platelet cryopreservation using second-messenger effector and low-dose (2%) dimethyl sulfoxide. In vitro evaluation of post-thawing platelet activity with the platelet function analyzer. (2000) (9)
- Cetuximab for treatment of metastatic colorectal cancer. (2006) (9)
- 448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS. (2014) (9)
- Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study (2012) (9)
- A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors (2020) (9)
- Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 (2019) (9)
- Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies (2020) (9)
- Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas (2021) (8)
- Second-Line Chemotherapy with Bleomycin, Methotrexate, and Vinorelbine (BMV) for Patients with Squamous Cell Carcinoma of the Head, Neck and Esophagus (SCC-HN&E) Pretreated with a Cisplatin-Containing Regimen: A Phase II Study (2003) (8)
- Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. (2000) (8)
- Activity and safety of capecitabine and irinotecan (CPT-11) in association as first line chemotherapy in advanced colorectal cancer (ACRC) (2001) (8)
- A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment (2020) (8)
- Clinical utilisation of human haematopoietic progenitors elicited in peripheral blood by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). (1994) (8)
- The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD (2007) (8)
- Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases (2022) (8)
- Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. (2014) (8)
- Quantization of CD34+ Peripheral Blood Hematopoietic Progenitors for Autografting in Cancer Patients (1993) (8)
- The use of GM-CSF and peripheral blood stem cells (PBSC) minimises haematological toxicity following a myeloablative course of chemo-radiotherapy. (1992) (8)
- Pathophysiology, clinical manifestations and supportive care of metastatic brain cancer. (2001) (8)
- Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients (2016) (8)
- Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study (2014) (8)
- High-dose cyclophosphamide in patients with operable breast cancer: recombinant human GM-CSF ameliorates drug-induced leukopenia and thrombocytopenia. (1990) (8)
- 364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases (2020) (8)
- Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). (2021) (8)
- Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC). (2011) (7)
- Preoperative FU-based chemoradiation with or without weekly oxaliplatin in locally advanced rectal cancer: Preliminary safety findings of the STAR (Studio Terapia Adiuvante Retto)-01 randomized trial (2007) (7)
- Regorafenib for metastatic colorectal cancer (2013) (7)
- Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substitute (1997) (7)
- Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial (2018) (7)
- Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data (2008) (7)
- 2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study (2015) (7)
- Panitumumab (pmab) efficacy and patient-reported outcomes in metastatic colorectal cancer patients with wild-type KRAS tumor status. (2008) (7)
- Primitive hematopoietic progenitor cells are present in peripheral blood autografts. (1994) (7)
- PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER (2013) (7)
- 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations (2020) (7)
- Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon wool-adherent mature cells. (1994) (6)
- Monosomy 7 syndrome. (1982) (6)
- Total body irradiation and high-dose melphalan with bone marrow transplantation at Istituto Nazionale Tumori, Milan, Italy. (1990) (6)
- Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis (2021) (6)
- KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients (2009) (6)
- Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. (2013) (6)
- Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion. (2007) (6)
- Clinical Application of Growth Factors for Collection of Circulating Hematopoietic Progenitors in Breast Cancer Patients Treated with Highdose Cyclophosphamide (1993) (6)
- Breaking Barriers in HER2+ Cancers. (2020) (6)
- Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies (2021) (6)
- High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. (2015) (6)
- Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status (2017) (6)
- Methodologies to estimate circulating hematopoietic progenitors for autologous transplantation in cancer patients. (1991) (6)
- Role of recombinant human granulocyte-macrophage colony stimulating factor for large scale collection of peripheral blood stem cells for autologous transplantation. (1990) (6)
- A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status. (2007) (6)
- Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma. (2005) (5)
- Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). (2015) (5)
- MC13-0022 Resection rates and survival in patients with wild-type KRAS/NRAS metastatic colorectal cancer and liver metastases: Data from the PRIME study (2013) (5)
- Heterogeneity of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF). (1990) (5)
- Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer. (2013) (5)
- Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy? (2013) (5)
- Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies. (2005) (5)
- Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib (2013) (5)
- The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC). (2012) (5)
- Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC). (2013) (5)
- E13Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months (2015) (5)
- 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (5)
- International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method. (2018) (5)
- Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. (2006) (5)
- 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline (2020) (5)
- Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. (2001) (5)
- 247 ORAL BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer (2008) (5)
- Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update (2012) (5)
- Hepatitis B and acute lymphoblastic leukemia. (1982) (5)
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC (2022) (4)
- Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. (2020) (4)
- Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. (2022) (4)
- Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study. (2014) (4)
- A Case of Metastatic Axillary Lymph Nodes Involvement from Unknown Primary Cancer: Clinical Usefulness of [99mTc]-Sestamibi (1998) (4)
- Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review (2022) (4)
- Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial. (2021) (4)
- Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial (2014) (4)
- Colostral T lymphocytes detected by intracytoplasmic and membrane markers. (1982) (4)
- Colorectal Cancer Treated With Cetuximab Patients With Chemotherapy-Refractory Metastatic p . G 13 D Mutation With Outcome inKRASAssociation of Supplementary material (2010) (4)
- Towards the integration of hematopoietic stem cells into therapy of breast cancer? (1999) (4)
- Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). (2012) (4)
- Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI (2009) (4)
- Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B). (2014) (4)
- High Sensitivity and Specificity Assay for Detection of Leukemia/Lymphoma Cells in Human Bone Marrow a (1987) (4)
- Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study (2022) (4)
- A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS) (2008) (4)
- Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study. (2012) (4)
- Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids (2021) (4)
- Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 (2019) (4)
- 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies (2020) (4)
- Immunotoxin mediated killing of clonable T-lymphocytes infiltrating an irreversibly rejected human renal allograft. (1989) (3)
- Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. (2006) (3)
- P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer (2012) (3)
- A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study. (2015) (3)
- Concurrent Small-Cell Transformation and Emergence of Trans-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma. (2019) (3)
- 6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy (2011) (3)
- Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. (2010) (3)
- Lipid‐lowering therapy of everolimus‐related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) (2018) (3)
- Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results (2008) (3)
- Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4 (2016) (3)
- Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial (2006) (3)
- High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer (2004) (3)
- MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases (2019) (3)
- Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (2011) (3)
- Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer (2016) (3)
- Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation. (2015) (3)
- 8C.04: POSSIBLE ROLE OF ARTERIAL FUNCTION IN CANCER TREATMENT TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ONCOLOGIC RESPONSE (2015) (3)
- Delphi initiative for early-onset colorectal cancer (DIRECt). International Management Guidelines. (2022) (3)
- Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC). (2009) (3)
- Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth (2018) (3)
- Rationale and clinical results of multi-target treatments in oncology. (2007) (3)
- 3025 POSTER Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study (2007) (3)
- A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer. (2018) (3)
- Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy. (2007) (3)
- Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses (2019) (3)
- Detection of occult leukemic cells in the autologous bone marrow graft of a patient with T-cell acute lymphoblastic leukemia by a highly specific and sensitive assay. (1989) (3)
- Epidermal Growth Factor Receptor Antibody Therapies − Anti Impairs the Response of Metastatic Colorectal Cancers to Oncogenic Activation of the RAS / RAF Signaling Pathway (2007) (3)
- Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS). (2014) (3)
- Iron Supplementation during Treatment with Erythropoiesis-Stimulating Agents for Cancer-Related Anemia (2008) (3)
- Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. (2008) (3)
- Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer (2022) (3)
- Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature (2008) (2)
- Understanding the Value of Response and Early Tumour Shrinkage (ETS) in Pts with Wt kras MCRC Treated with Panitumumab (P) Plus Folfox (F) (2012) (2)
- Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA (2021) (2)
- The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review. (2022) (2)
- 478OEfficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) (2017) (2)
- Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib. (2020) (2)
- MC13-0024 Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study (2013) (2)
- Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study) (2007) (2)
- PLS. plenary session (2012) (2)
- 1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis (2020) (2)
- Iron supplement in cancer patients receiving erythropoietin. (2004) (2)
- Digital PCR quanti fi cation of MGMT methylation re fi nes prediction of clinical bene fi t from alkylating agents in glioblastoma and metastatic colorectal cancer (2015) (2)
- Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients’ avatars. (2014) (2)
- 507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer (2020) (2)
- D26Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL (2016) (2)
- Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC). (2021) (2)
- Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial (2016) (2)
- In vitro purging with 4-hydroperoxycyclophosphamide and its effects on the hematopoietic and stromal elements of human bone marrow (1985) (2)
- PD-0008COMPREHENSIVE KRAS AND NRAS MUTATION ANALYSIS: PREDICTIVE BIOMARKERS IN A PHASE 3 PANITUMUMAB MONOTHERAPY STUDY OF METASTATIC COLORECTAL CANCER (MCRC) (2013) (2)
- A standardized flow cytometry protocol for mobilized peripheral CD34+ cells estimation and collection for autotransplantation in cancer patients. (1994) (2)
- Application of histology-agnostic treatments in metastatic colorectal cancer. (2022) (2)
- Clinical Usefulness and Optimal Harvesting of Peripheral Blood Stem Cells Mobilized by High Dose Cyclophosphamide and Recombinant Human GM-CSF (1993) (2)
- PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress) (2021) (2)
- Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation? (2012) (2)
- Personalized therapeutic strategies in HER2-driven gastric cancer (2021) (2)
- Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts) (2007) (2)
- Detection of bone marrow minimal disease in non-Hodgkin's lymphoma patients by gene rearrangement analysis. (1989) (2)
- PD-0024OVERALL SURVIVAL (OS) AND TUMOUR SHRINKAGE OUTCOMES IN PATIENTS WITH SYMPTOMATIC/ASYMPTOMATIC METASTATIC COLORECTAL CANCER (MCRC): DATA FROM THE PRIME STUDY (2013) (2)
- OC-006: Concomitant treatment (CRT or cetuximab/RT) with or without induction TPF in Locally Advanced head and neck (2015) (2)
- Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp). (2021) (2)
- Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study. (2018) (2)
- 539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study (2020) (2)
- P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens (2020) (2)
- Myeloablation with diaziquone: in vitro assessment. (1987) (2)
- Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy (2012) (1)
- Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials (2018) (1)
- Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (2022) (1)
- 691PREGIONAL SUBANALYSIS OF THE PHASE III MPACT TRIAL: NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR PATIENTS (PTS) WITH METASTATIC PANCREATIC CANCER (PC). (2014) (1)
- A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets). (2022) (1)
- O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) (2012) (1)
- O-0031EVALUATION OF KRAS, NRAS, AND BRAF MUTATIONS IN PRIME: PANITUMUMAB WITH FOLFOX4 AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) (2013) (1)
- 6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) (2011) (1)
- Absence of c‐Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer (2003) (1)
- Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study (2012) (1)
- Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature (2021) (1)
- Ef fi cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study (2014) (1)
- 540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (2020) (1)
- Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. (1991) (1)
- Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer (2016) (1)
- Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study (2016) (1)
- The early breast cancer (EBC) biological characteristics from NEMESI, an Italian retrospective, observational study. (2010) (1)
- Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin. (1987) (1)
- Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer (2018) (1)
- Reply to E. Hawkes et al (2010) (1)
- Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research. (2014) (1)
- 6656 Evaluation of sE-Selectin and circulating Vascular Endothelial Growth Factor (VEGF) in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II DOCETUX Study) (2009) (1)
- 385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study (2020) (1)
- A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
- Abstract B229: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer (2009) (1)
- Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy. (2010) (1)
- Comparability testing of KRAS mutations and association with efficacy from a phase 3 randomized trial of panitumumab (pmab) (2009) (1)
- Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC) (2010) (1)
- Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. (2010) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. (2018) (1)
- New technology and changing parameters of leukapheresis for blood cell transplantation. (1999) (1)
- Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial (2020) (1)
- The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. (2019) (1)
- Rationale and Clinical Results of Multi-target Treatments in Oncology (2007) (1)
- Nasopharyngeal Carcinoma (NPC) : The value of 18-Florine Fluorodeoxyglucose (FDG) Positron Emission Tomography Computed Tomography (PET / CT) in comparison to conventional imaging modalities Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) (2007) (1)
- Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (2012) (1)
- Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK. (2013) (1)
- 446P Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study (2021) (1)
- Prognostic significance of KRas mutation rate in metastatic colorectal cancer patients (2015) (1)
- Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. (2017) (1)
- 2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC) (2015) (1)
- AOS13 Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of three phase 3 studies (2012) (1)
- Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation (2020) (1)
- European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the french ITAC group and the EBMT Solid Tumour Working Party (2006) (1)
- Abstract PR01: Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer (2015) (1)
- Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features. (2023) (1)
- P-0255INTERIM ANALYSIS RESULTS OF ABOVE PHASE II STUDY WITH BEVACIZUMAB IN PATIENTS WITH INITIALLY NOT RESECTABLE/BORDERLINE RESECTABLE COLORECTAL LIVER-LIMITED METASTASES (2013) (1)
- Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial. (2010) (1)
- O-010KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer (2015) (1)
- Experience with a Patient-Adapted Approach to Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis (2004) (1)
- Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program. (2014) (1)
- A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
- Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements. (2017) (1)
- Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type (2004) (1)
- Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases (2020) (1)
- Prospective evaluation of pulmonary function after total body irradiation (TBI), high-dose melphalan and autologous bone marrow transplantation (ABMT) (1989) (0)
- Very large increase in circulating human hematopoietic precursor cells following high dose single agent chemotherapy (1989) (0)
- DAY-TO-DAY PRACTICE Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature (2008) (0)
- SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth (2019) (0)
- hematopoietic and microenvironmental elements of human bone marrow Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the (2011) (0)
- Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies (2018) (0)
- Cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharingeal carcinoma. (2010) (0)
- Contents Vol. 54, 2008 (2008) (0)
- E08Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients (2015) (0)
- Circulating Hemopoietic Precursors after High-Dose Cyclophosphamide: Efficacy of In Vivo GM-CSF Administration (1990) (0)
- [Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy]. (1989) (0)
- Epidermal Growth Factor Receptor Expression and Activation in Nonseminomatous Germ Cell Tumors 1 (2001) (0)
- 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary perito (2022) (0)
- The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer. (2016) (0)
- 1716PTRKA expression and NTRK1 gene copy number across solid tumors (2017) (0)
- Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC). (2014) (0)
- Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer (2019) (0)
- Mutational signatures of early-onset colorectal cancer. (2019) (0)
- 2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
- PD-0023 Benefit of Adding Panitumumab (pmab) To 1St/2Nd-Line Chemotherapy in Patients with KRAS WT mCRC: A Number-Needed-To-Treat (NNT) Analysis (2012) (0)
- D17Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial (2016) (0)
- High-dose sequential chemotherapy (HDSC) with peripheral blood progenitor cells (PBPC) support for high-risk breast cancer (BC) (2007) (0)
- MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress. (2023) (0)
- Recombinant Human GM-CSF for Large-Scale Collection of Circulating Hematopoietic Progenitors in Cancer Patients Treated with High-Dose Cyclophosphamide (1990) (0)
- Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation (2023) (0)
- Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers (2017) (0)
- PD-026Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study (2016) (0)
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in KRAS wild-type Advanced Biliary Tract Cancer : a randomized , Phase II trial ( Vecti-BIL Study ) Running title GEMOX and Panitumumab in wt KRAS BTC (2016) (0)
- Autologous EBV-specific cytotoxix T lymphocytes for the treatment of EBV-related nasopharyngeal carcinoma (2005) (0)
- MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer author ( s ) list : (0)
- D28The FUNNEL: a precision medicine project for metastatic colorectal cancer (2016) (0)
- Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (2023) (0)
- Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers. (2017) (0)
- Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort. (2021) (0)
- Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (2021) (0)
- Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. (2015) (0)
- Hematopoietic stem cell transplantation in the treatment of lymphoma (1991) (0)
- Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study. (2022) (0)
- HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial. (2023) (0)
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. (2023) (0)
- targets of retroviral-mediated gene transfer Human peripheral blood hematopoietic progenitors are optimal (2011) (0)
- Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer (2018) (0)
- PD-028Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab (2016) (0)
- Poster session Thursday 12 December - PM: 12/12/2013, 14:00-18:00 * Location: Poster area (2013) (0)
- [Long-term hematopoietic reconstitution after myeloablative antitumor therapy and circulating hematopoietic stem cell transplantation]. (1996) (0)
- P.26 Adjuvant treatment for elderly patients with colon cancer in ten Italian medical oncology units (2007) (0)
- Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab (2007) (0)
- Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease (2016) (0)
- 27 Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology divisions in Italy (2006) (0)
- Phase II study of dacarbazine for metastatic colorectal cancer: Final results with MGMT analysis. (2017) (0)
- L02*Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study (2015) (0)
- [4th National Conference of Medical Oncology. Evolution of the technology and clinical objectives of antitumor therapy]. (2002) (0)
- Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. (2013) (0)
- E11Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within clinical studies based on individual molecular alterations at Niguarda Cancer Center (2015) (0)
- K-Ras and B-Raf mutations and anti-EGFR antibody treatment (2008) (0)
- Abstract 3834: Tracking CAD-ALK gene translocation in urine and plasma of a colorectal cancer patient treated with ALK blockade (2017) (0)
- Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients (2015) (0)
- Abstract 6262: Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide (2022) (0)
- Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. (2008) (0)
- 54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients (2014) (0)
- Ex vivo generation and expansion of autologous anti-tumor CTL lines for adoptive cell therapy in patients with solid tumors. (2006) (0)
- Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2008) (0)
- S29Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies - THE CORNUCOPIA STUDY (2016) (0)
- 84MO A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 (2020) (0)
- Therapeutics (1904) (0)
- A randomised phase II study of cetuximab plus gemcitabine/cisplatin combination in advanced pancreatic cancer (APC) (2007) (0)
- Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial (2012) (0)
- Expert in the field of circulating biomarkers for GI tumors (2019) (0)
- Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer. (2019) (0)
- Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study (2012) (0)
- Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura: a pilot study (2000) (0)
- Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. (2022) (0)
- ASSESSMENT OF TUMOR GENOTYPES IN METASTATIC COLORECTAL CANCER (MCRC): MUTATIONS BEYOND KRAS CODONS 12 AND 13 AS PREDICTIVE BIOMARKERS OF RESPONSE TO PANITUMUMAB (PMAB) IN A RANDOMIZED, PHASE 3 STUDY (2011) (0)
- O-0014 Effect of Post-Protocol anti-EGFR mAb Therapy on Survival Outcomes in Patients with Wild-Type Kras MCRC Treated with Panitumumab Plus Chemotherapy (2012) (0)
- Abstract B069: Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells (2019) (0)
- Abstract A087: Empowering precision medicine in metastatic colorectal cancer: preliminary results from the FUNNEL platform (2018) (0)
- Short-term effect of anti-VEGF drugs on heart and vessels (2013) (0)
- PD-024Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma (2016) (0)
- Abstract 2829: Identification of the role of SRBC methylation-associated gene silencing as predictive factor of oxaliplatin secondary resistance in metastasic colorectal cancer patients (2014) (0)
- MC13-0021 Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study (2013) (0)
- The right chance for temozolomide in metastatic colorectal cancer? (2018) (0)
- 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress (2021) (0)
- Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study (2021) (0)
- Ascaris Suum Extract: Polyclonal Activator Properties as Possible Tools for Investigating in Vitro IgE Production in Humans (1981) (0)
- Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report (2023) (0)
- Authors' Disclosures of Potential Conflicts of Interest Theauthorsindicatednopotentialconflictsofinterest. (2004) (0)
- Subject Index Vol. 54, 2008 (2008) (0)
- Allogeneic peripheral blood stem cell transplantation following reduced-intensity chemotherapy for refractory sarcoma (2001) (0)
- Pharmacodynamics of sorafenib: An exploratory assessment of circulating biomarkers in a phase II metastatic breast cancer trial (2007) (0)
- Agnostos precision medicine project in patients (PTS) with cancer of unknown primary (CUP) (2016) (0)
- 228PPATTERN OF DIHYDROPYRIMIDINE DEHYDROGENASE GENETIC VARIANTS IN PATIENTS WITH VARIOUS DEGREES OF TOLERABILITY OF FLUOROPYRIMIDINE TREATMENT. (2014) (0)
- Erratum: Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon wool-adherent mature cells (Bone Marrow Transplantation (1994) 14 (863-869)) (1995) (0)
- Restricted Saporin Immunotoxins : Activity Against B-Cell Lines and Chronic Lymphocytic Leukemia Cells (2005) (0)
- 426P Impact of preoperative chemoradiotherapy on tumor infiltrating lymphocytes in locally advanced rectal cancer: The SMART-STAR study (2020) (0)
- Dendritic cells from peripheral blood cd34+ progenitors in cancer patients treated with high dose sequential theraphy (1996) (0)
- Abstract 5419: A unique pattern of heterogeneous MMR protein expression in colorectal cancer unveils different degrees of tumor mutational burden and distinct tumor microenvironment features (2022) (0)
- Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer (2019) (0)
- 6571 POSTER Open-label study of pemetrexed (P) alone or in combination with a platinum in patients (pts) with peritoneal mesothelioma (PM): results from the international expanded access program (EAP) (2007) (0)
- Abstract LB-75: Blood-based molecular detection of acquired resistance to anti-EGFR therapies in colorectal cancer patients. (2013) (0)
- 887 CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA) WITH KARYORRHEXIS (1985) (0)
- Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases (2020) (0)
- Abstract CT214: AlfaOmega- a master protocol empowering precision research in colorectal cancer (2019) (0)
- [Disequilibrium of lymphocytic sub-groups in an child with familial lymphohistiocytosis]. (1983) (0)
- PD-006Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study (2015) (0)
- Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies. (2002) (0)
- Panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): results from the randomised phase III PRIME study (2010) (0)
- P-284Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup (2015) (0)
- Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial. (2012) (0)
- Assessing clinical appropriateness on a population basis within a regional cancer network. (2012) (0)
- Abstract LB-220: Translational research with RG7160 (GA201) leads to a phase II clinical study in combination with FOLFIRI in 2nd line metastatic colorectal cancer (mCRC) (2012) (0)
- Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study. (2016) (0)
- Abstract A57: Extended RAS analysis in patients (pts) with untreated metastatic colorectal cancer (mCRC): Results from the PRIME and PEAK studies (2014) (0)
- Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the star (Studio terapia adiuvante retto)-01 randomized phase III trial (2010) (0)
- PD-0019 Benefit of Panitumumab (pmab) as Monotherapy in Patients with WT KRAS mCRC: A Number-Needed-To-Treat (NNT) Analysis (2012) (0)
- Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001 (2016) (0)
- immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates Synthesis and characterization of an antihuman T-lymphocyte saporin (2013) (0)
- Cardiotoxicity of novel molecular targeted therapies of cancer (2011) (0)
- Abstracts from the 13th National Congress of the Italian Society of Cardiovascular Prevention (SIPREC), Naples, 12–14 March 2015 (2015) (0)
- A CUP OF COFFEE FOR ALLERGIC RHINITIS (1982) (0)
- Abstract B110: Heterogeneous genetic alterations emerge during acquired resistance to anti-EGFR therapy in colorectal cancer. (2013) (0)
- Abstract B11: Whole-exome sequencing analysis of urine transrenal tumor DNA in metastatic colorectal cancer patients (2020) (0)
- Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. (2023) (0)
- ricin A-chain immunotoxin Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) (1987) (0)
- Erratum: Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substitute (Bone Marrow Transplantation (1996) 18 (619-623)) (1997) (0)
- Phase II study of dacarbazine for metastatic colorectal cancer with determined MGMT status. (2017) (0)
- BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. (2023) (0)
- [Clinical use of hematopoietic growth factors]. (1991) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Salvatore Siena?
Salvatore Siena is affiliated with the following schools:
